## 3 Results
### Functional Outcomes after 9 Weeks
#### 3.1.2 Functional Capacity  
After adjustment for differences in the baseline characteristics, there was a significant improvement in comparison to the baseline value in functional capacity assessed by peak VO\({}_{2}\) only in the adherent patients: \(\Delta\)peak VO\({}_{2}\) 1.06 mL/kg/min (95% CI: 0.72, \begin{table}
\begin{tabular}{c c c c c} \hline \hline  & **Adherent Patient Group** & \multicolumn{2}{c}{**Partially Adherent and**} \\  & **Baseline** & **9 th Week** & **Baseline** & **9 th Week** \\ \hline I & 45 (12.9\%) & 92 (26.3\%) & 7 (15.2\%) & 7 (15.2\%) \\ \hline II & 249 (71.1\%) & 215 (61.4\%) & 28 (60.9\%) & 26 (56.5\%) \\ \hline III & 56 (16.0\%) & 43 (12.3\%) & 11 (23.9\%) & 13 (28.3\%) \\ \hline \hline \end{tabular} NYHA—New York Heart Association; between-groups analysis: baseline: \(p=0.318\); 9 th week \(p=0.009\).  
\end{table} 
Table 2: Change in distribution of NYHA class from baseline to week 9 comparison by degree of patients’ adherence to hybrid comprehensive telerehabilitation. \begin{table}
\begin{tabular}{c c c c c} \hline \hline  & **Hybrid Comprehensive** & **Adherent Patients** & \multicolumn{2}{c}{**Partially Adherent and**} \\  & **Telerehabilitation Group** & **Group** & **Non-Adherent Patients Group** & \(p\) \\  & **(n = 396)** & **(n = 350)** & **(n = 46)** & \\ \hline \multicolumn{4}{c}{Treatment, n (\%)} \\ \hline Beta-blocker & 380 (96.0) & 335 (95.7) & 45 (97.8) & 0.706 \\ \hline ACEI/ARB & 369 (93.2) & 329 (94.0) & 40 (87.0) & 0.110 \\ \hline Digoxin & 51 (12.9) & 44 (12.6) & 7 (15.2) & 0.614 \\ \hline Loop diuretics & 292 (73.7) & 257 (73.4) & 35 (76.1) & 0.700 \\ \hline Spironolactone/eplerenone & 328 (82.8) & 290 (82.9) & 38 (82.6) & 0.966 \\ \hline Aspirin/clopidogrel & 222 (56.1) & 205 (58.6) & 17 (37.0) & **0.005** \\ \hline Anticoagulants & 117 (29.5) & 104 (29.7) & 13 (28.3) & 0.839 \\ \hline NOAC & 65 (16.4) & 52 (14.9) & 13 (28.3) & **0.021** \\ \hline Statins & 321 (81.1) & 292 (83.4) & 29 (63.0) & **<0.001** \\ \hline CIEDs & 314 (79.3) & 275 (78.6) & 39 (84.8) & 0.328 \\ \hline ICD & 193 (61.5) & 170 (61.8) & 23 (59.0) & 0.689 \\ \hline \hline \end{tabular} SD, standard deviation; BDI-II, Beck Depression Inventory II; SF-36, Medical Outcome Survey Short Form 36; NYHA, New York Heart Association class; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; NOAC, non-vitamin K antagonist oral anticoagulants; CIEDs, cardiovascular implantable electronic devices; ICD, implantable cardiovetter-defibrillator.  
\end{table} 
Table 1: _Cont._1.40 mL/kg/min). In the partially and non-adherent patients, this favorable effect was not observed \(\Delta\) peak VO\({}_{2}\) 0.95 mL/kg/min (95% CI: \(-\)0.13, 2.04 mL/kg/min). Although the results were statistically significant, due to the fact that the partially and non-adherent group was small, this could possibly be considered a trend. Yet, between-group analysis showed that there were no statistically significant differences between the groups regarding the improvement (\(\Delta\)) in peak VO\({}_{2}\) (\(p=0.855\)). Impact of Patients' Adherence to HCTR on Long-Term Prognosis during 14-26 Months after the Intervention Was Completed  
There were 46 deaths during the 14-26 months follow-up in the HCTR arm with mortality rates at 24 months 11.6%. Non-adherence or partially adherence was associated with statistically significantly higher risk of cardiovascular (CV) mortality (hazard ratio (HR) = 2.62; 95% CI: (1.12-6.13); \(p=0.021\)); composite endpoints combining: all-cause mortality or HF hospitalization (HR = 1.71; 95% CI: (1.02-2.86); \(p=0.038\)), and CV mortality or HF hospitalization (HR = 1.89; 95% CI: (1.13-3.16); \(p=0.014\)). This association in terms of all-cause mortality or HF hospitalization and CV mortality or HF hospitalization remained after controlling for adjustment variables (HR = 1.79; 95% CI: (1.06-3.04); \(p=0.030\)), (HR = 1.99; 95% CI: (1.17-3.39); \(p=0.012\)) respectively Table 3, Figures 1-3.